Small Biotech Firm NNVC is Working on the Next Revolutionary Antiviral Medicine

The success of penicillin led to an explosion in the development of... [Crystal Clear News](2FZW1haWw9dHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tJmFpZD00JnB0bj1DQ04%3D/41425e1bf7a87706082f46ba79ae0490h?x-ew-link-index=1) [hidden]( IN PARTNERSHIP WITH NANOVIRICIDES, INC 3D/5af360a4544191bb7ed8e969b2b26dcdh?x-ew-link-index=1 [NanoViricides, Inc. (NYSE: NNVC) is an Innovative Biotech Company that is Taking a Novel, Game-Changing Approach to Eradicating Many Respiratory Viruses Once and For All Including the Tripledemic Threat Of COVID, RSV, and the FLU!](3D/5af360a4544191bb7ed8e969b2b26dcdh?x-ew-link-index=2) The success of penicillin led to an explosion in the development of antibacterials. But what about fighting viruses? One NYSE-traded biotech company called NanoViricides, Inc. (NYSE: NNVC) is on a solid footing to revolutionize the treatment of antiviral infections with game-changing antiviral nanomedicines.These drugs could be as revolutionary as antibiotics and do not rely on immune systems making them great for seniors and children! The company’s lead drug candidate NV-387 is aimed to treat RSV, Covid-19, Long Covid, Influenza, Bird Flu H5N1, and other respiratory viral infections. Recently NanoViricides, Inc. (NYSE: NNVC) had big news revealing that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported. In contrast, lethally infected animals in the Ribavirin oral treatment group showed progressive lung pathology, demonstrating progressive inflammation in the lung tissue which resulted in moderate levels of inflammation as well as infected cells in the inflammatory infiltrate on day 10, increasing to severely infected lungs with alveolitis and severe pneumonia by day 13. All animals in the ribavirin-treated RSV infected group died by 14 days. No approved treatment currently exists for RSV other than ribavirin. This means a safe and effective treatment remains an unmet medical need and offers this company an incredible market opportunity. [Discover how an antiviral drug such as NNVC’s NV-387 (if found to be effective in human clinical studies) could catapult the company into the spotlight!](3D/5af360a4544191bb7ed8e969b2b26dcdh?x-ew-link-index=3) Your email address is on this list as a result of a subscription, information request, competition, or other correspondence you may have had with us in the past. If you would like to be removed from our list, check the email address this newsletter was sent to and use the following link: [Unsubscribe](3D%3D/a431b54eabe62b2be2ca4e86a27d49cah). Privacy policy available [here](3D%3D/cedd000f8cbd5a29b2cf77e354563f1ch?x-ew-link-index=1). [CrystalClearNews.com](3D/31723611d639833edeaa75360d90344fh?x-ew-link-index=1) 4023Kennett Pike Wilmington, Delaware, 19807 United States of America This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE American: NNVC) from Interactive Offers. CrystalClearNews.com receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1870. Other than the compensation received for this advertisement sent to subscribers, CrystalClearNews.com and its principals are not affiliated with either NanoViricides, Inc. (NYSE American: NNVC) or Interactive Offers. CrystalClearNews.com and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither CrystalClearNews.com nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from CrystalClearNews.com to buy or sell any security. CrystalClearNews.com has not evaluated the accuracy of any claims made in this advertisement. CrystalClearNews.com recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results.